Summary
The occurrence of cross-border illicit trade and seizures of counterfeit goods by EU-authorities continues to rise year on year. The OECD and the EU’s Intellectual Property Office (EUIPO) estimate that imports of counterfeit and pirated goods are worth nearly half a trillion dollars a year, or around 2.5% of global imports, with US, Italian and French brands the hardest hit. In the EU, the Falsified Medicines Directive (FMD) requires the introduction of a full tracking and tracing system by February 2019. Medicine packs will need to contain a unique identifier (2D barcode) and an anti-tampering device (such as labels), i.e. a technical means to ensure that the content of the package has not been tampered with. At present, there is no technology available on the global market which allows a true authentication of pharmaceutical products themselves, all initiatives so far concentrate on packaging only. SRAP technology overcomes this gap. SRAP is compatible with future FMD regulations; and can provide for fast, reliable and full tracking-and-tracing along the supply chain without the need to destroy product during authentication, while enabling true authentication on the product level - not just the package; and if necessary SRAP solutions provide for a database-independent authentication in the field (via mobile phone) – a very strong set of functionalities that combine to an extremely strong USP. The objectives of feasibility study are as follows – identify 3 potential commercial partners from pharmaceutical industry, define full-scale terms of reference jointly with the 3 partners identified and prepare a full business plan for a new joint venture entity.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/808887 |
| Start date: | 01-04-2018 |
| End date: | 30-09-2018 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
The occurrence of cross-border illicit trade and seizures of counterfeit goods by EU-authorities continues to rise year on year. The OECD and the EU’s Intellectual Property Office (EUIPO) estimate that imports of counterfeit and pirated goods are worth nearly half a trillion dollars a year, or around 2.5% of global imports, with US, Italian and French brands the hardest hit. In the EU, the Falsified Medicines Directive (FMD) requires the introduction of a full tracking and tracing system by February 2019. Medicine packs will need to contain a unique identifier (2D barcode) and an anti-tampering device (such as labels), i.e. a technical means to ensure that the content of the package has not been tampered with. At present, there is no technology available on the global market which allows a true authentication of pharmaceutical products themselves, all initiatives so far concentrate on packaging only. SRAP technology overcomes this gap. SRAP is compatible with future FMD regulations; and can provide for fast, reliable and full tracking-and-tracing along the supply chain without the need to destroy product during authentication, while enabling true authentication on the product level - not just the package; and if necessary SRAP solutions provide for a database-independent authentication in the field (via mobile phone) – a very strong set of functionalities that combine to an extremely strong USP. The objectives of feasibility study are as follows – identify 3 potential commercial partners from pharmaceutical industry, define full-scale terms of reference jointly with the 3 partners identified and prepare a full business plan for a new joint venture entity.Status
CLOSEDCall topic
SMEInst-13-2016-2017Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Search
